VivoSeq
Metabolic & Endocrine

NAFLD

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

NAFLD is an early-stage landscape with 0 programs across 5 companies. The most active players are Conatus Pharmaceuticals Inc., Hanmi Pharmaceutical Company Limited, Gannex Pharma Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

81/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Conatus Pharmaceuticals Inc.

0 programs

PreclinicalHanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited

0 programs

PreclinicalG

Gannex Pharma Co., Ltd.

0 programs

PreclinicalE

Enanta Pharmaceuticals, Inc

0 programs

PreclinicalS

Sinew Pharma Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed13 · 68%
Recruiting2 · 11%
Withdrawn2 · 11%
Unknown status1 · 5%
Terminated1 · 5%

Clinical Trials

Trial Activity

19 trials

Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
Recruiting·UUniversity of California, San Diego·N/A·NCT06586281·20 enrolled
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
Recruiting·ZZhujiang Hospital·Phase 4·NCT06449833·100 enrolled
Different Doses of ZED1227 vs. Placebo in NAFLD
Completed·—·Phase 2·NCT05305599·186 enrolled
Follow-up of NAFLD Patients With MRI-PDFF
Completed·—·Phase 4·NCT04910178·80 enrolled
A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases
Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT02077374·38 enrolled
Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
Completed·SSichuan Leshan Traditional Chinese Medicine Hospital·Phase 1·NCT05523648·92 enrolled
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
Completed·Hanmi Pharmaceutical Company Limited logoHanmi Pharmaceutical Company Limited·Phase 1·NCT03744182·66 enrolled
DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.
Completed·GGannex Pharma Co., Ltd.·Phase 1·NCT04845646·24 enrolled
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT
Completed·—·N/A·NCT03836937·70 enrolled
Ketohexokinase Inhibition in NAFLD
Completed·MMaastricht University Medical Center·Phase 2·NCT05463575·15 enrolled
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD
Completed·EEnanta Pharmaceuticals, Inc·Phase 1·NCT02918929·146 enrolled
The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine
Completed·FFudan University·Phase 1·NCT01677325·40 enrolled
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
Completed·MMediciNova·Phase 2·NCT02681055·19 enrolled
Probiotic Supplementation IN NAFLD Patients
Completed·—·Phase 4·NCT06074094·50 enrolled
Glycemic Effect of Diazoxide in NAFLD
Completed·—·Phase 1·NCT05729282·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)